Exabis Library
Welcome to the e-CCO Library!
P393: Outcome of treat to target strategy in paediatric patients with Crohn’s disease and ulcerative colitis on infliximab
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P393: Treatment patterns of patients with perianal fistulizing Crohn’s disease from a US administrative claims database
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P394 Preoperative factors associated with prolonged postoperative in-hospital length of stay in patients with Crohn’s disease undergoing intestinal resection or strictureplasty
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P394: A prospective analysis of body composition in patients with Inflammatory Bowel Disease and changes during biologic therapy
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P394: Contribution of the CDEIS in the new therapeutic approach of Crohn's disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P394: Long-term perineal reoperation and wound healing after proctectomy or ileal pouch-anal anastomosis extirpation in patients with Inflammatory Bowel Disease – a retrospective multicentre study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P394: Preoperative serum vedolizumab levels do not predict postoperative outcomes in inflammatory bowel disease (IBD)
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P394: Prolonged azathioprine treatment reduces the need for surgery in early Crohn's disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P394: Psychosexual dysfunction in a cohort of Greek inflammatory bowel disease patients in clinical remission: preliminary results
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P394: Serological biomarkers of type III and IV collagen remodeling predict and monitor infliximab treatment response in patients with Inflammatory Bowel Disease
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P395 Management of pouch vaginal fistulae in ulcerative colitis: A 35-year experience
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P395: Dermatological reactions associated with anti–TNF therapy in inflammatory bowel disease- an 12 year experience
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P395: Etrolizumab demonstrated no difference among doses in symptomatic and endoscopic-based evaluation of remission in anti-TNF-α-naïve patients in a post-hoc analysis of the phase 2 ulcerative colitis trial (EUCALYPTUS)
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P395: Impact of mirikizumab therapy on histologic measures of intestinal inflammation in a Phase 2 study of patients with moderately to severely active Crohn’s disease
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P395: Postoperative immunosuppressive therapies decrease the risk of second intestinal surgery in patients with Crohn’s disease: a retrospective cohort study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P395: Proactive Therapeutic Drug Monitoring May Reduce the Need for Combination Therapy in Inflammatory Bowel Disease Patients Treated with Infliximab
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P395: Real-life prospective experience with adalimumab in ulcerative colitis in Italy: preliminary results of a pilot study
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P395: Short-term clinical efficacy and safety of teduglutide for Crohn's disease patients with short bowel syndrome
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P396 Pharmacokinetics and circulating total lymphocyte count pharmacodynamic response from single and multiple oral doses of etrasimod in Japanese and Caucasian healthy male subjects
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P396: Acceptance of switch, patient satisfaction and adverse events after switch from adalimumab originator to biosimilar SB5 in patients with Inflammatory Bowel Disease in a real-life setting
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM